prikaz prve stranice dokumenta Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases
  Preuzmi
PDF 3.13 MB
Znanstveni rad - Izvorni znanstveni rad
Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases
HemaSphere, 6 (2022), 12; e807. https://doi.org/10.1097/HS9.0000000000000807
Galušić, Davor; Bašić-Kinda, Sandra; Pijuk, Anđela; Milunović, Vibor; Dreta, Barbara; Franjić, Neven; Coha, Božena; Sinčić-Petričević, Jasminka; Gaćina, Petar; Pejsa, Vlatko; Lucijanić, Marko; Aurer, Igor

Citirajte ovaj rad

Galušić, D., Bašić Kinda, S., Pijuk, A., Milunović, V., Dreta, B., Franjić, N. ... Aurer, I. (2022). Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases. HemaSphere, 6. (12). doi: 10.1097/HS9.0000000000000807

Galušić, Davor, et al. "Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases." HemaSphere, vol. 6, br. 12, 2022. https://doi.org/10.1097/HS9.0000000000000807

Galušić, Davor, Sandra Bašić Kinda, Anđela Pijuk, Vibor Milunović, Barbara Dreta, Neven Franjić, Božena Coha, et al. "Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases." HemaSphere 6, br. 12 (2022). https://doi.org/10.1097/HS9.0000000000000807

Galušić, D., et al. (2022) 'Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases', HemaSphere, 6(12). doi: 10.1097/HS9.0000000000000807

Galušić D, Bašić Kinda S, Pijuk A, Milunović V, Dreta B, Franjić N, i sur.. Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases. HemaSphere [Internet]. 12.2022. [pristupljeno 23.12.2024.];6(12). doi: 10.1097/HS9.0000000000000807

D. Galušić, et al., "Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases", HemaSphere, vol. 6, br. 12, Prosinac 2022. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:450646. [Citirano: 23.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:450646
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases
AutorDavor Galušić
AutorSandra Bašić-Kinda
AutorAnđela Pijuk
AutorVibor Milunović
AutorBarbara Dreta
AutorNeven Franjić
AutorBožena Coha
AutorJasminka Sinčić-Petričević
AutorPetar Gaćina
AutorVlatko Pejsa
AutorMarko Lucijanić
AutorIgor Aurer
Autorova ustanova(Klinički bolnički centar Rijeka)
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za internu medicinu)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Infektologija
Sažetak (hrvatski)
Obinutuzumab (G) has become part of front-line treatment of follicular lymphoma (FL) based on results of a large randomized study. Data on patients treated outside of clinical trials are lacking. We have retrospectively investigated efficacy and safety of G-based immunochemotherapy regimens in 114 patients treated in a real-life setting during a period of 2 years, largely coinciding with the COVID-19 pandemic. The response rate was 93.8%; 18-months overall (OS) and progression-free survival (PFS) were 88% and 84%, respectively. Patients treated with G-cyclophosphamide, vincristine and glucocorticoid + doxorubicine (CHOP) had statistically significantly superior OS and PFS compared to patients treated with G-bendamustine (G-B) (P = 0.002 and P = 0.006, respectively) due to an increase in lethal infections, most notably COVID-19, in the latter group. A total of 12 patients died during follow-up; 9 of 61 treated with G-B, 1 of 49 treated with G-CHOP and 2 of 4 treated with G-cyclophosphamide, vincristine and glucocorticoid (CVP). SARS-CoV-2 infection was diagnosed in 20 (17.5%) patients. All of the 7 treated with G-CHOP recovered, while 4 of 12 treated with G-B died. Immunoglobulin levels and severity of neutropenia were similar between the groups. In multivariate analysis, G-B in comparison to G-CHOP was an independent prognostic factor (P = 0.044, hazard ratio = 9.81) after adjustment for age, sex and Follicular Lymphoma International Prognostic Index (FLIPI). Based on our experience G has excellent antilymphoma activity in patients receiving front-line treatment for FL in real-life setting, but during the COVID-19 pandemic, it should be preferentially combined with CHOP, at least in patients younger than 65.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaHemaSphere
Brojčani podacivol. 6, br. 12, e807
e-ISSN2572-9241
DOIhttps://doi.org/10.1097/HS9.0000000000000807
URN:NBNurn:nbn:hr:184:450646
Datum objave publikacije2022-12
URL dokumentahttps://journals.lww.com/10.1097/HS9.0000000000000807
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje-Nekomercijalno-Bez prerada 4.0 međunarodna (CC BY-NC-ND 4.0)
Datum i vrijeme pohrane2023-02-01 08:14:04